Levocabastine

Drug Profile

Levocabastine

Alternative Names: Histimet; Levophta; Levostab; Livistin; Livocab; Livostin; R 50547

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.
  • Developer Janssen-Cilag; Kyowa Hakko Kirin; Nippon Shinyaku; Santen Pharmaceutical
  • Class Antiallergics; Piperidines; Sedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Allergic conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 06 May 2008 Launched for Allergic conjunctivitis in European Union (Intraocular)
  • 06 May 2008 Launched for Allergic conjunctivitis in United Kingdom (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top